Atopic Dermatitis

The submission of roflumilast’s supplemental New Drug Application to the FDA by Arcutis follows the conclusion of the INTEGUMENT-PED and INTEGUMENT-OLE studies.

The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.

This approval announcement by Galderma follows the previous FDA approval of nemolizumab for prurigo nodularis.

This interim analysis highlights positive findings from the Measure Up 1 and 2 studies regarding upadacitinib for patients with atopic dermatitis.

These data provide insight into characteristics of those who choose to discontinue systemic therapies for eczema.

This assessment of dupilumab for pediatric and adult patients with moderate-to severe eczema treated for up to 5 years confirms the drug efficacy and safety across age groups.

These topline findings regarding MH004, or tofacitinib etocomil ointment 1.0%, demonstrated efficacy for this twice-daily pan-Jak inhibitor in adolescents and adults with eczema.

This analysis evaluated the frequency of peanut-sensitized infants and toddlers being sensitized to other types of nuts.

In this analysis in Thailand, video education’s impact on patient guardians’ knowledge was assessed with the aim of reducing eczema severity.

MJH Life Sciences, parent company of HCPLive, has acquired the RAD Annual Meeting, a premier CME-certified conference advancing dermatology knowledge and research.

These data on patients in Japan with eczema suggest there was sustained effectiveness in these patients’ clinical signs and in patient-reported outcomes.

In this analysis, patterns of global access to biologic drugs for patients with atopic dermatitis were explored among 50 countries.

New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.

More patients with atopic dermatitis on stapokibart than on placebo achieved ≥ 75% improvement in Eczema Area and Severity Index over 52 weeks.

Many with moderate-to-severe atopic dermatitis do not reach treatment targets in 12 months, underscoring a need for proactive management strategies.

In these data presented at the Fall Clinical Dermatology conference, population-based data on utilization and duration of systemic corticosteroid exposure was highlighted.

These long-term extension trial data from ADORING 3 highlight tapinarof cream’s efficacy in adults and children aged 2 years and older with atopic dermatitis.

These data from the ADapt study, presented at Fall Clinical, suggest improvements among patients with eczema given lebrikizumab-lbkz who had been previously treated with dupilumab.

These data were presented at Fall Clinical, highlighting the reductions in Eczema Area and Severity Index scores and the overall long-term safety profile of tralokinumab-ldrm.

At the Fall Clinical Dermatology conference, Chovatiya presented on chronic hand eczema and facts about its pathophysiology, diagnosis, and management.

The drug’s favorable risk-benefit profile and sustained efficacy through 76 weeks was highlighted in this analysis’s findings.

This overview highlights our upcoming conference coverage at the Fall Clinical Dermatology Conference in Las Vegas.

This analysis reconfirms the efficacy of dupilumab using a single-center design, a large sample size, and patients with chronic hand eczema.

These data suggest more immediate benefits to alitretinoin, though ultraviolet therapy was shown to be cost-effective after 10 years of use.

In this cohort study, the drug survival rates of methotrexate, cyclosporine A, and dupilumab for adolescents with eczema were assessed along with reasons for discontinuation.

In this single center analysis, investigators highlighted results of dupilumab treatment after 3 years among patients with moderate-to-severe eczema.

These data highlight barriers to pediatric treatments for eczema, providing potential strategies for caregivers and patients for adherence improvement.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.